Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P43146 (tumour suppressor)
 5,935 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

H-ras-transformed NIH3T3 cells that overexpressed a human melanoma-associated antigen ME491 (44-3H) were generated by transfection with the cloned ME491 antigen gene followed by a 'panning' selection, and effects of the antigen overexpression on H-ras-mediated malignant phenotypes were studied. Although in vitro growth properties of the 44-3H overexpresser cells, both anchorage-dependent and -independent, were practically the same as those of the 44-1C control cells, 44-3H cells exhibited less malignant phenotypes in athymic nude mice (in vivo), i.e. decreased tumourigenicity after subcutaneous inoculation and prolonged survival time after intraperitoneal inoculation, compared with 44-1C cells. These results suggested that overexpression of ME491 antigen partially suppressed malignant phenotypes of H-ras-transformed NIH3T3 cells in athymic nude mice through co-operating with a factor(s) or mechanism(s) that exist in vivo but not in vitro. Thus, ME491 antigen might act as a tumour suppressor under some circumstances.
Melanoma Res
PMID:Overexpression of the human melanoma-associated antigen ME491 partially suppresses in vivo malignant phenotypes of H-ras-transformed NIH3T3 cells in athymic nude mice. 182 25

Genetic and molecular analyses of Drosophila have shown that tumorigenesis may arise from inactivation of single genes controlling cell growth and differentiation. Recessive mutations in a series of genes interrupt the differentiation of primordial cells and result in overgrowth, producing either hyperplasia or neoplasia. In mutant animals tumours form in either the optic centres of the larval brain, the imaginal discs or the haemopoietic organs. In Drosophila 17 genetic loci giving rise to neoplasia and six loci producing hyperplasia have been identified. The lethal(2)giant larvae gene constitutes the prototype of these genes. Its molecular cloning and analysis have demonstrated that the tumor phenotype results from a lack of gene function. Furthermore, tumour prevention was achieved by introducing a normal copy of l(2)gl into the genome of l(2)gl- deficient animals, showing that the l(2)gl gene behaves as a tumour suppressor or anti-oncogene. Melanomas of genetic origin develop in interspecies hybrids of the fish Xiphophorus. The melanoma appears when a sex linked chromosomal gene (Tu) is present among the progeny animals lacking an autosomal locus Differentiation, which acts as a tumour suppressor gene. A sequence homologous to the erb-B gene can be associated to the sex chromosomal Tu locus. This gene encodes a receptor tyrosine kinase related to the EGF-receptor, and its activation and overexpression are thought to play a critical part in melanoma formation.
 ...
PMID:The fruit fly Drosophila and the fish Xiphophorus as model systems for cancer studies. 210 23

The goal of genetic analysis of malignant melanoma is to identify genes involved in the transformation of melanocytes and melanoma tumour progression. Three basic approaches have been used to analyze tumour progression in melanoma, and these include: (1) performing genetic linkage analysis on familial melanoma to identify the chromosomal location of genes which predispose individuals to melanoma; (2) examining tumours cytogenetically to identify frequently rearranged regions of the genome which presumably mark the location of genes involved in the evolution of melanoma; and (3) screening melanomas, using molecular techniques, to identify mutated oncogenes or tumour suppressor genes that play crucial roles in melanoma development. These studies provide strong evidence that genes on chromosomes 1, 6, 7 and 9 are involved in the aetiology of human melanoma.
 ...
PMID:Genetics of melanoma. 210 27

Genetic tumours of Xiphophorus are one of the classical experimental models that underline the concept that cancers develop as a result of abnormal gene expression. Formal genetics has indicated that cancer development in Xiphophorus starts when oncogenes are expressed abnormally due to elimination of tumour suppressor genes. The suppressor gene Diff seems to suppress malignancy by controlling terminal differentiation of cells. It appears now that control of terminal differentiation may also be one of the properties of human tumour suppressor loci, in particular the Rb gene. Although it is difficult at this point to envision which molecular or biochemical function of tumour suppressor genes we might be able to identify, research on tumour suppression will at least allow another glimpse at how basic mechanisms of cell differentiation and multiplication operate. It is not clear, however, if elimination of tumour suppressor genes alone is sufficient to elicit the fully malignant phenotype. Cytogenetic studies have shown various nonrandom chromosomal abnormalities in those human tumours in which elimination of a tumour suppressor gene seems to be a critical step in tumorigenesis. In Xiphophorus, it is obvious from our molecular studies that additional genetic events can contribute to the malignant phenotype. Of these, amplification of cellular DNA may have a role in malignant progression of melanomas. At this point, the exact contribution of amplification to genetic melanoma is unclear. Judging from the role of amplification in human and murine tumours, the significance of amplification, in addition to suppressor elimination, in melanomas of Xiphophorus is likely to be high.
 ...
PMID:Genetic suppression of malignancy. 268 Sep 48

The mapping of the naevoid basal cell carcinoma syndrome (NBCCS) and the Ferguson-Smith syndrome to the same region on chromosome arm 9q has led to speculation that the two conditions may reflect different mutations within the same gene. Loss of heterozygosity of 9q alleles in both familial and sporadic basal cell carcinomas (BCCs) suggests that the NBCCS gene on 9q is acting as a tumour suppressor gene. Although LOH of 9q markers has not been studied in squamous cell neoplasms from patients with the Ferguson-Smith syndrome, chromosome 9 allele loss has been reported in sporadic squamous cell carcinomas (SCCs) of the skin. In order to characterise further the deleted region on chromosome 9 in BCCs and SCCs of the skin we have examined a series of non-melanoma skin cancers using a panel of highly informative microsatellite markers. Forty-four BCCs and 49 SCCs were studied. Loss of heterozygosity of one or more 9q markers was seen in 33 of the 44 BCCs. Only 4 of the 33 BCCs with 9q loss showed loss of 9p markers. Twenty-two BCCs showed loss of all informative 9q markers. Partial or interstitial 9q deletions were seen in 5 BCCs, and in 3 of these 5 BCCs the breakpoint occurred within the currently defined NBCCS locus. Chromosome 9 loss was seen in 16 of 49 SCCs. In contrast to the low frequency of 9p loss in BCCs, LOH of 9p markers was a common finding in SCCs, occurring in 15 of the 16 SCCs with chromosome 9 loss. In 5 SCCs 9p loss occurred with retention of 9q alleles.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Delineation of two distinct deleted regions on chromosome 9 in human non-melanoma skin cancers. 753 25

Active unspecific immunotherapy in an adjuvant or palliative setting has been shown to enhance survival in melanoma patients, and gene therapy now offers new perspectives for active specific immunotherapy. Gene therapy includes the transfer of genetic material performed by either viral or non-viral methods and in vivo or ex vivo. For melanoma the following approaches are suggested: vaccination with tumour-specific, HLA-associated antigens using peptides or 'naked DNA', vaccination with melanoma cells transfected with cytokine genes or B7, adoptive immunotherapy with specific T-lymphocytes or transfected tumour-infiltrating lymphocytes, or transfection of tumour cells with a tumour suppressor gene whose dysfunction plays a crucial role in melanoma.
 ...
PMID:[Strategies for gene therapy of melanoma]. 760 92

Mutations of the p53 tumour suppressor gene are common to many human malignancies. Although increased p53 expression has been observed in cutaneous malignant melanoma, mutations of the p53 gene appear to be infrequent. We examined 140 benign and malignant paraffin-embedded melanocytic lesions for p53 protein expression by immunohistochemistry, using the monoclonal anti-p53 antibody DO-7 and a microwave method of antigen retrieval. Fifteen naevi and 25 melanomas were further analysed for p53 mutations within exons 5-8 of the p53 gene. DNA was extracted from paraffin sections and screening for mutations was carried out using PCR-SSCP. We demonstrated p53 protein expression in 33% of naevi (17 out of 51), 35% of primary melanomas (20 out of 58), and 70% of metastatic lesions (15 out of 21). p53 expression in benign lesions was weaker than in malignant lesions in intensity and percentage of cells staining. p53 protein expression in melanomas increased in intensity and percentage of cells staining with tumour progression. In 25% (three out of 12) of metastatic melanomas p53 mutations were detected by PCR-SSCP and increased expression of p53 protein was observed in these tumours. p53 gene mutations were not detected in any benign melanocytic lesions. We demonstrate that antigen retrieval techniques increase p53 immunoreactivity in paraffin embedded melanocytic tissues. p53 protein expression in melanomas increases with depth of tumour invasion. As p53 gene mutations occur infrequently in malignant melanoma, other mechanisms are proposed to influence p53 protein expression in melanocytic lesions.
Melanoma Res 1995 Apr
PMID:p53 gene mutation and expression in naevi and melanomas. 762 Mar 45

The cytoskeletal protein talin is localised on the cytoplasmic face of the integrin family of adhesion receptors in cellular junctions with the extracellular matrix. Using polymerase chain reaction amplification and DNA from a panel of human-rodent somatic cell hybrids, we have assigned the talin gene to chromosome 9p. Deletions in 9p have been implicated in a variety of cancers, including malignant melanoma, and the concept that talin might be a candidate tumour suppressor gene is discussed.
 ...
PMID:Localisation of the human gene encoding the cytoskeletal protein talin to chromosome 9p. 763 75

Combined multi-point linkage analysis in seven Dutch families with FAMMM syndrome confirmed the location of a melanoma susceptibility (MLM) gene in the 9p21 area. The occurrence of a shared high-risk haplotype in six of the families strongly suggests a founder effect in the Leiden region. No indication for locus heterogeneity was observed. Recently, the CDKN2 (p16) gene, an important regulator of the cell cycle, was isolated from the 9p21 region. A 19-bp germline deletion in the CDKN2 gene was detected in the high-risk haplotype, suggesting CDKN2 to be identical to MLM. Loss of heterozygosity studies in melanoma and pancreatic carcinoma from gene carriers strongly support the view that CDKN2 is a general tumour suppressor gene predisposing not only to melanoma but also to other malignancies. Interestingly, the occurrence of apparent clinical FAMMM cases with melanoma but without the high-risk deletion haplotype suggests the necessity of additional (naevus) genes to explain the complete FAMMM phenotype.
Melanoma Res 1995 Jun
PMID:CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families. 764 May 18

Cell division is controlled by a series of positive and negative regulators which act at sequential points throughout the cell cycle. Disturbance of these checks could contribute to cancer by allowing excessive cell proliferation. The point in G1 at which cells irrevocably commit to DNA synthesis is controlled by protein complexes consisting of cyclin-dependent kinases (CDK4 or CDK6) and cyclins (D1, D2 or D3). These complexes are inhibited by low molecular weight proteins, such as p16INK4 (refs 1,2), p15INK4B (ref. 3) and p18 (ref. 4). Deletion or mutation of these CDK-inhibitors could lead to unchecked cell growth, suggesting that members of the p16INK4 family may be tumour suppressor genes. The recent detection of p16INK4 (MTS1) mutations in familial melanoma kindreds, many human tumour cell lines, and primary tumours is consistent with this idea. Previously, we described eight germline p16INK4 substitutions in 18 familial melanoma kindreds. Genetic analyses suggested that five mutations predisposed carriers to melanoma, whereas two missense mutations had no phenotypic effect. We now describe biochemical analyses of the missense germline mutations and a single somatic mutation detected in these families. Only the melanoma-predisposing mutants were impaired in their ability to inhibit the catalytic activity of the cyclin D1/CDK4 and cyclin D1/CDK6 complexes in vitro. Our data provide a biochemical rationale for the hypothesis that carriers of certain p16INK4 mutations are at increased risk of developing melanoma.
 ...
PMID:Mutations associated with familial melanoma impair p16INK4 function. 764 80


1 2 3 4 5 6 7 8 9 10 Next >>